News

In addition, the parties have agreed to jointly seek dismissal with prejudice of all claims and counterclaims asserted in the ongoing litigation between the parties. Ligand and Rockefeller

Net loss in 2008 was $98.1 million, or $1.03 per share, compared with a net income of $281.7 million, or $2.87 per share, in 2007. For the fourth

The partnership will enable clinicians all over the world to deliver boost brachytherapy as part of the whole breast irradiation procedure, providing a superior treatment option with the

Response Biomedical and Roche Diagnostics signed a strategic partnership in June 2008 to commercialize Response’s cardiovascular tests. The first project approved for funding is to complete a submission

Net loss for the full year 2008 was $93.6 million, compared to $160 million for the full year 2007. Net loss per share was $0.26 and $1.53 for

Net loss for the 12 months ended December 31, 2008 was $62.5 million, or $2.48 per diluted share, compared to a net income of $28.2 million, or $1.08

The new San Diego research facility now houses expanded research laboratories for peptide medicinal chemistry, bioanalytical and DMPK (distribution, metabolism and Pharmacokinetics), molecular and cell biology, cell culture,

The recently completed trials include both a multiple ascending dose study in subjects aged 18-55 and a separate study conducted in subjects 65 years of age or older.

These products currently include Prospera brachytherapy seeds, SurTRAK needles and strands and various accessories used primarily in the treatment of prostate cancer. North American Scientific (NASM) will receive